However, this trend appears inconsistent in glioma as inhibitory immune checkpoints such as PD-1, CTLA-4 and TIM-3 are consistently upregulated in M1/M2 GAMs which have been shown to significantly decrease patient prognosis (48, 49). The gene discussed is CTLA4; the disease is glioma.